InnFocus MicroShunt Versus Trabeculectomy Study

NCT ID: NCT01881425

Last Updated: 2022-10-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

732 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-15

Study Completion Date

2020-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma medications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity.

Clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to monitor eye health. At the 1 and 2 year follow up, diurnal (IOP taken in the morning, mid-day, and afternoon in the same day) IOP evaluation will be done. Annual follow up will occur up to 2 years. The primary effectiveness endpoint is 20% or greater reduction in IOP from pre-op medicated IOP at 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

InnFocus MicroShunt

InnFocus MicroShunt

Group Type EXPERIMENTAL

InnFocus MicroShunt

Intervention Type DEVICE

An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Trabeculectomy

glaucoma surgery to reduce IOP

Group Type ACTIVE_COMPARATOR

Glaucoma Surgery

Intervention Type PROCEDURE

An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glaucoma Surgery

An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Intervention Type PROCEDURE

InnFocus MicroShunt

An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a "fornix-based" conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria: - POAG on maximum tolerated glaucoma meds - Medicated ≥15mmHg and ≤40mmHg - Exclusion Criteria: - Previous conjunctival incisional ophthalmic surgery - Anticipated need for additional ocular surgery during the study - Secondary glaucoma - Any condition that prevents the device implantation or trabeculectomy in the superior region of the study eye
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

InnFocus Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Palmberg, M.D., Ph.D.

Role: STUDY_DIRECTOR

Bascom Palmer Eye Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eye Physicians and Surgeons of Arizona

Glendale, Arizona, United States

Site Status

Arizona Eye Consultants

Tucson, Arizona, United States

Site Status

Vold Vision

Fayetteville, Arkansas, United States

Site Status

University of California at Davis Eye Center

Davis, California, United States

Site Status

UCLA Jules Stein Eye Institute

Los Angeles, California, United States

Site Status

Ophthalmic Consultants of Connecticut

Fairfield, Connecticut, United States

Site Status

Inter-Mountain Eye Care

Eagle, Idaho, United States

Site Status

Chicago Glaucoma Consultants and CGC Eye Center

Glenview, Illinois, United States

Site Status

Eugene and Marilyn Glick Eye Institute

Indianapolis, Indiana, United States

Site Status

Stiles Eyecare Excellence

Overland Park, Kansas, United States

Site Status

Washington Eye Physicians and Surgeons

Chevy Chase, Maryland, United States

Site Status

Minnesota Eye Consultants, PA

Bloomington, Minnesota, United States

Site Status

Midwest Eye Surgery Center

Omaha, Nebraska, United States

Site Status

New York Eye and Ear Infirmary of Mt. Sinai

New York, New York, United States

Site Status

Glaucoma Consultants of the Capital Region

Slingerlands, New York, United States

Site Status

Cincinnati Eye Institute

Cincinnati, Ohio, United States

Site Status

Ophthalmic Surgeons and Consultants of Ohio

Columbus, Ohio, United States

Site Status

Dean McGee Eye Institute

Oklahoma City, Oklahoma, United States

Site Status

Ophthalmic Partners of Pennsylvania

Bala-Cynwyd, Pennsylvania, United States

Site Status

Glaucoma Associates of Texas

Dallas, Texas, United States

Site Status

Ophthalmology Associates

Fort Worth, Texas, United States

Site Status

The Robert Cizik Eye Clinic

Houston, Texas, United States

Site Status

Rashid, Rice, Flynn and Reilley Eye Associates

San Antonio, Texas, United States

Site Status

Specialty Eye Care

Bellevue, Washington, United States

Site Status

Pole Ophtalmologique de la Clinique Mutualiste

Pessac, Bordeaux, France

Site Status

Pisa University Hospital Cisanello

Pisa, , Italy

Site Status

University Eye Clinic Maastricht

Maastricht, , Netherlands

Site Status

Hospital Clínico San Carlos

Madrid, , Spain

Site Status

Moorfields Eye Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States France Italy Netherlands Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Park J, Rittiphairoj T, Wang X, E JY, Bicket AK. Device-modified trabeculectomy for glaucoma. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD010472. doi: 10.1002/14651858.CD010472.pub3.

Reference Type DERIVED
PMID: 36912740 (View on PubMed)

Baker ND, Barnebey HS, Moster MR, Stiles MC, Vold SD, Khatana AK, Flowers BE, Grover DS, Strouthidis NG, Panarelli JF; INN005 Study Group. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study. Ophthalmology. 2021 Dec;128(12):1710-1721. doi: 10.1016/j.ophtha.2021.05.023. Epub 2021 May 27.

Reference Type DERIVED
PMID: 34051211 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

INN005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Primary Tube Versus Trabeculectomy Study
NCT00666237 COMPLETED PHASE4